In the search for non-opioid options to treat pain, Australian biotech Mesoblast (ASX: MSB) has turned to a stem cell approach, which is currently in late-stage development for chronic low back pain. However, interviewed experts say its potential for Phase III success is uncertain due to scant human evidence with this stem cell product for treating pain.
Even if it reaches the market, the therapy would face various access restrictions, according to reporting from Shuan Sim, pharma writer for the investigative news team at analytics firm GlobalData.
Mr Sim comments: “While Mesoblast’s MPC-06-ID is projected to be a multi-billion-dollar asset, experts whom I spoke to do not believe the therapy would reach blockbuster status easily.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze